On-line hemodiafiltration in the large RISCAVID study.

Area of Science:

• Nephrology
• Cardiology
• Inflammation Research

Background:

• Chronic kidney disease stage 5 patients on hemodialysis (CKD-5D) have high mortality, particularly cardiovascular (CV) mortality.
• CKD-5D patients face traditional and non-traditional CV risk factors, including those from uremia and dialysis treatment.
• Chronic inflammation significantly contributes to accelerated atherosclerosis in CKD-5D.

Purpose of the Study:

• To present new insights into chronic inflammation and its impact on CV mortality and anemia in CKD-5D patients.
• To assess parameters of chronic inflammation, CV mortality, and anemia management in a large hemodialysis population.
• To explore the potential of on-line hemodiafiltration in improving CKD-5D patient outcomes.

Main Methods:

• Prospective observational study (RISCAVID) on a large hemodialysis population in Tuscany, Italy.
• Assessment of various parameters of chronic inflammation.
• Evaluation of gross/CV mortality and anemia management.

Main Results:

• Hemodialysis patients exhibit significantly higher CV mortality risk compared to the general population.
• On-line hemodiafiltration shows potential in improving chronic inflammation, fluid overload, left ventricular hypertrophy, anemia, and quality of life.
• The study provides insights into the relationship between inflammation, mortality, and anemia in CKD-5D.

Conclusions:

• Despite advances, CKD-5D mortality remains high, with CV disease being a major concern.
• On-line hemodiafiltration offers potential benefits beyond waste product removal for CKD-5D patients.
• Broadening the concept of biocompatibility in HD systems is crucial for managing inflammation and improving patient survival.